Back to search

Article

Patient-derived tumor organoids from resected non-small cell lung cancers for high-throughput response testing with approved and repurposed drugs

2023-10-21

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> The five-year survival for non-metastatic non-small cell lung cancer (NSCLC) patients undergoing curative surgery remains poor at ∼50% that is due to locoregional and/or distant metastatic recurrences. Patient-derived tumor organoids (PDTOs) have high potential as clinically relevant high-throughput drug testing platforms to personalize and improve treatment of NSCLC patient...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b4485d98-ecdf-5ff1-b1a7-ac517321eb9a
DOI
10.1101/2023.10.18.562944
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Patient-derived tumor organoids from resected non-small cell lung cancers for high-throughput response testing with approved and repurposed drugsDOI 10.1101/2023.10.18.562944
Select a neighboring publication to make it the new centre.